The OPUS registry was set up to collect long-term (five years) real-world clinical practice safety data in patients with moderate-to-severe UC treated with infliximab . This safety profile was compared with that of UC patients treated with conventional therapies. It demonstrated a higher rate of colectomy in infliximab-treated patients. For most patients it became necessary after they discontinued infliximab (≥90 days) and probably was related to a more severe disease at baseline.
The prospective, non-randomised, observational study followed more than 2,000 UC patients in routine practice across 14 European countries. These patients were enrolled to receive treatment with either infliximab or conventional therapies, as determined by their treating physician.
At any time during the study, the patient’s therapy could be changed to any other UC therapy, based on the physician’s clinical judgment. In the intention-to-treat main analysis, Cox propo...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Cobitolimod induces anti-inflammatory effects by balancing Th17/T-reg cell response Next Article
ILC1 distribution predicts response to ustekinumab »